Related news from
Fri, 16 Oct 2026 15:55:39 +0000	Cencora (COR): 3 Reasons We Love This Stock Cencora has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6% to $341.69 per share while the index has gained 9.7%.
Fri, 16 Oct 2026 15:11:29 +0000	Is Cencora (COR) Undervalued Or Is Raised Guidance Already Priced In? Cencora has delivered a powerful long run for shareholders, and the question now is whether the current share price lines up with the cash the business can generate. With cash flows in focus, recent gains invite a closer look at what the underlying economics of the company really support. Over the past 5 years Cencora has returned 192.4%, which puts a lot of accumulated optimism on the line if its future cash generation does not keep pace. Management has highlighted a pharmaceutical centric...
Fri, 25 Sep 2026 12:00:00 +0000	Cencora Elects Robert E. Sanchez to Its Board of Directors CONSHOHOCKEN, Pa., September 25, 2026--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026.
Mon, 21 Sep 2026 23:02:08 +0000	Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027 Cencora (NYSE:COR) executives said the company expects its specialty-focused strategy to support continued growth into fiscal 2027, citing demand in oncology and retina, expanded physician-services capabilities and momentum in its international businesses. Speaking at the Morgan Stanley Global Heal
Mon, 21 Sep 2026 10:02:04 +0000	Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference Cencora (NYSE:COR) executives highlighted the company’s specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens. Chief Executive Offi
Sat, 19 Sep 2026 12:38:37 +0000	Cencora (COR) Raised Guidance and Bought Back $1B. What’s the Catch? On August 5, Cencora (NYSE:COR) reported results for its fiscal third quarter, which closed on June 30, and the headline numbers looked clean. Revenue rose 5.1% to $84.8 billion, adjusted earnings per share climbed 12.0% to $4.48, and management raised its full-year adjusted EPS outlook to $17.75 to $17.95. The company also repurchased $1 billion […]
Thu, 24 Sep 2026 20:22:01 +0000	AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026? AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.
Thu, 15 Oct 2026 14:36:05 +0000	AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year.
Mon, 12 Oct 2026 23:51:01 +0000	AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? AbbVie trades at a 40% valuation discount but faces revenue concentration risk, while Eli Lilly's cardiometabolic dominance commands a premium.
Sun, 04 Oct 2026 14:34:57 +0000	Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.
Fri, 02 Oct 2026 12:00:00 +0000	Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release CONSHOHOCKEN, Pa., October 02, 2026--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2026 on Wednesday, November 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 4, 2026.
Fri, 02 Oct 2026 09:42:03 +0000	2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Thu, 01 Oct 2026 22:41:02 +0000	AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.
Mon, 28 Sep 2026 13:18:36 +0000	1 of Wall Street’s Favorite Stocks with Impressive Fundamentals and 2 We Turn Down Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Fri, 25 Sep 2026 21:22:01 +0000	AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.
Tue, 22 Sep 2026 13:32:00 +0000	Can CAH's MSO Expansion Unlock Growth in Specialty Care Delivery? CAH is expanding its MSO strategy across specialty care, with Solaris and broader services aimed at scaling physician networks.
Sun, 20 Sep 2026 14:08:24 +0000	Cencora (COR) Lifts EPS Outlook And Buyback, Is The Stock Still Below Fair Value? Cencora (COR) just combined a stronger fiscal third quarter, a higher full year adjusted EPS outlook, and a US$1b buyback with plans to brief investors at two New York healthcare conferences. Despite the upbeat earnings message, Cencora’s share price has eased in the short term, with a 7 day share price return of down 3.98% and a 30 day share price return of down 2.91% from US$308.78. At the same time, a 90 day share price return of 13.82% and a 1 year total shareholder return of 7.28% sit...
Tue, 06 Oct 2026 13:30:01 +0000	Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026? Eli Lilly's revenue surged 44.7% in 2025, but Novo Nordisk trades at less than a quarter of its valuation multiple, a stark contrast that reshapes the risk-reward calculus.
Thu, 24 Sep 2026 21:19:01 +0000	AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026? Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!